Trial Therapy’s Potential to Prevent Ovarian Cancer Relapses Supported by Mouse Study

Trial Therapy’s Potential to Prevent Ovarian Cancer Relapses Supported by Mouse Study
An investigational drug that boosts the response of natural killer (NK) cells — key players of first-line immune defenses — was recently shown to effectively decrease ovarian tumors in a mouse model of the cancer. The drug, called ALT-803, could also re-activate inactive NK cells isolated from ovarian cancer patients. Researchers now plan to study

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *